Systematic review / meta-analysis / 2023
Emblica officinalis fruit extract significantly reduced total cholesterol and LDL-C and raised HDL-C compared to placebo in adults with dyslipidemia.
A meta-analysis evaluated four randomized trials (N = 227) examining Emblica officinalis aqueous fruit extract versus placebo over 12 weeks in adults with dyslipidemia. The extract significantly decreased total cholesterol (SMD = -21.23 mg/dL, 95% CI: -34.22 to -8.25; P = 0.001) and LDL-C (SMD = -25.12 mg/dL, 95% CI: -40.24 to -10.00; P = 0.001), and increased HDL-C (SMD = 4.74 mg/dL, 95% CI: 0.40 to 9.07; P = 0.03). No statistically significant difference was seen in serum triglycerides (SMD = -22.28 mg/dL, 95% CI: -53.33 to 8.76; P = 0.16). High heterogeneity was present across all lipid outcomes (I2 between 72% and 93%), and findings were based on low certainty of evidence.
- Study type
- Systematic review and meta-analysis of randomized trials
- Who was studied
- Adult patients with dyslipidemia from 4 randomized trials (N = 227)
- What was measured
- Total cholesterol, LDL-C, serum triglycerides, HDL-C, and adverse events
THE PAPER
The Efficacy and Safety of Emblica officinalis Aqueous Fruit Extract among Adult Patients with Dyslipidemia: A Systematic Review and Meta-analysis.
Acampado LRT, Chiu HHC, Larrazabal RB, Arcellana AES, Añonuevo-Cruz MCS. Acta Med Philipp, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.